Therapy of membranous nephropathy in systemic lupus erythematosus

Seminars in Nephrology

Volumn 23, Issue 4, 2003, Pages 386-391

  Balow, James E ^a   Austin III, Howard A ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; CHLORAMBUCIL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; PREDNISONE; RAPAMYCIN;

CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; HYPERLIPIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; LIFESTYLE; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MEMBRANOUS GLOMERULONEPHRITIS; META ANALYSIS; NEPHROTIC SYNDROME; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 0041887377     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0270-9295(03)00056-1     Document Type: Article

References (41)

1. Balow JE, Boumpas DT, Austin HA III: Systemic lupus erythematosus and the kidney, in: Lahita RG (ed): Systemic Lupus Erythematosus (ed 4). San Diego, CA, Academic Press, (in press)
2. Korbet SM: Membranous lupus glomerulonephritis, in: Lewis EJ, Schwartz MM, Korbet SM (eds): Lupus Nephritis. Oxford, United Kingdom, Oxford University Press, 1999, pp 219-240
3. Adler SG, Johnson K, Louie JS, et al: Lupus membranous glomerulonephritis: Different prognostic subgroups obscured by imprecise histologic classifications. Mod Pathol 3:186-191, 1990
4. Muehrcke RC, Kark RM, Pirani CL, et al: Lupus nephritis: A clinical and pathologic study based on renal biopsies. Medicine (Baltimore) 35:1-145, 1957
5. Pollak VE, Pirani CL, Schwartz FD: The natural history of the renal manifestations of systemic lupus erythematosus. J Lab Clin Med 63:537-550, 1964
6. McCluskey RT: Lupus nephritis, in: Sommers SC (ed): Kidney Pathology Decennial. East Norwalk, CT, Appleton-Century-Crofts, 1975, pp 435-450
7. Baldwin DS, Lowenstein J, Rothfield NF, et al: The clinical course of the proliferative and membranous forms of lupus nephritis. Ann Intern Med 73:929-942, 1970
8. Churg J, Sobin L: Lupus nephritis, in Renal Disease: Classification and Atlas of Glomerular Diseases. New York, NY, Igaku-Shoin, 1982, pp 127-149
9. Churg J, Bernstein J, Glassock RJ: Lupus nephritis, in Renal Disease: Classification and Atlas of Glomerular Diseases (ed 2). New York, NY, Igaku-Shoin, 1995, pp 151-179
10. Donadio JV Jr, Hart GM, Bergstralh EJ, et al: Prognostic determinants in lupus nephritis: A long-term clinicopathologic study. Lupus 4:109-115, 1995
11. Pasquali S, Banfi G, Zucchelli A, et al: Lupus membranous nephropathy: Long-term outcome. Clin Nephrol 39:175-182, 1993
12. Gruppo Italiano per lo Studio della Nefrite Lupica (GISNEL): Lupus nephritis: Prognostic factors and probability of maintaining life-supporting renal function 10 years after diagnosis. Am J Kidney Dis 19:473-479, 1996
13. Bakir AA, Levy PS, Dunea G: The prognosis of lupus nephritis in African-Americans: A retrospective analysis. Am J Kidney Dis 24:159-171, 1994
14. Mercadal L, du Montcel ST, Nochy D, et al: Factors affecting outcome and prognosis in membranous lupus nephropathy. Nephrol Dial Transplant 17:1771-1778, 2002
15. Tateno S, Kobayashi Y, Shigematsu H, et al: Study of lupus nephritis: Its classification and the significance of subendothelial deposits. QJM 52:311-331, 1983
16. Leaker B, Fairley KF, Dowling J, et al: Lupus nephritis: Clinical and pathological correlation. QJM 62:163-179, 1987
17. Wang F, Looi LM: Systemic lupus erythematosus with membranous lupus nephropathy in Malaysian Patients. QJM 53:209-226, 1984
18. Sloan RP, Schwartz MM, Korbet SM, et al: Long-term outcome in systemic lupus erythematosus membranous glomerulonephritis. J Am Soc Nephrol 7:299-305, 1996
19. Huong DL, Papo T, Beaufils H, et al: Renal involvement in systemic lupus erythematosus: A study of 180 patients from a single center. Medicine (Baltimore) 78:148-166, 1999
20. Bono L, Cameron JS, Hicks JA: The very long-term prognosis and complications of lupus nephritis and its treatment. QJM 92:211-218, 1999
21. Appel GB, Cohen DJ, Pirani CL, et al: Long-term follow-up of patients with lupus nephritis: A study based on the classification of the World Health Organization. Am J Med 83:877-885, 1987
22. Appel GB, Pirani CL, D'Agati V: Renal vascular complications of systemic lupus erythematosus. J Am Soc Nephrol 4:1499-1515, 1994
23. Radhakrishnan J, Appel AS, Valeri A, et al: The nephrotic syndrome, lipids, and risk factors for cardiovascular disease. Am J Kidney Dis 22:135-142, 1993
24. Ordonez JD, Hiatt RA, Killebrew EJ, et al: The increased risk of coronary heart disease associated with nephrotic syndrome. Kidney Int 44:638-642, 1993
25. Ward MM: Premature morbidity from cardiovascular and cerebrovascular diseases in women with system lupus erythematosus. Arthritis Rheum 42:338-346, 1999
26. Falaschi F, Ravelli A, Martignoni A, et al: Nephrotic-range proteinuria, the major risk factor for early atherosclerosis in juvenile-onset systemic lupus erythematosus. Arthritis Rheum 43:1405-1409, 2000
27. Al-Herz A, Ensworth S, Shojania K, et al: Cardiovascular risk factor screening in systemic lupus erythematosus. J Rheumatol 30:493-496, 2003
28. Remuzzi G, Ruggenenti P, Perico N: Chronic renal diseases: Renoprotective benefits of renin-angiotensin system inhibition. Ann Intern Med 136:604-615, 2002
29. Keane WF: Metabolic pathogenesis of cardiorenal disease. Am J Kidney Dis 38:1372-1375, 2001
30. Donadio JV Jr, Burgess JH, Holley KE: Membranous lupus nephropathy: A clinicopathologic study. Medicine (Baltimore) 56:527-536, 1977
31. Donadio JV Jr: Treatment of membranous nephropathy in systemic lupus erythematosus. Nephrol Dial Transplant 7:97-104, 1992 (suppl 1)
32. Gonzales-Dettoni HG, Tron F: Membranous nephropathy in systemic lupus erythematosus. Adv Nephrol 14:347-364, 1984
33. Moroni G, Maccario M, Banfi G, et al: Treatment of membranous lupus nephritis. Am J Kidney Dis 31:681-686, 1998
34. Chan TM, Li FK, Hao WK, et al: Treatment of membranous lupus nephritis with nephrotic syndrome by sequential immunosuppression. Lupus 8:545-551, 1999
35. Radhakrishnan J, Kunis CL, D'Agati V, et al: Cyclosporine treatment of membranous lupus nephropathy. Clin Nephrol 42:147-154, 1994
36. Hallegua D, Wallace DJ, Metzger AL, et al: Cyclosporine for lupus membranous nephritis: Experience with ten patients and review of the literature. Lupus 9:241-251, 2000
37. Austin HA, Vaughan EM, Balow JE: Lupus membranous nephropathy: Controlled trial of prednisone, pulse cyclophosphamide, and cyclosporine A. J Am Soc Nephrol 11:81A, 2000 (abstr)
38. Warner LM, Adams LM, Sehgal SN: Rapamycin prolongs survival and arrests pathophysiologic changes in murine systemic lupus erythematosus. Arthritis Rheum 37:289-297, 1994
39. Wang W, Chan YH, Lee W, et al: Effect of rapamycin and FK506 on mesangial cell proliferation. Transplant Proc 33:1036-1037, 2001
40. Balow JE, Boumpas DT, Austin HA III: Lupus nephritis, in Brady HR, Wilcox CS (eds): Therapy in Nephrology and Hypertension (ed 2). London, Saunders, 2003, pp 153-164
41. Kolasinski SL, Chung JB, Albert DA: What do we know about lupus membranous nephropathy? An analytic review. Arthritis Rheum 47:450-455, 2002